【摘要】 目的:探讨急性白血病患者多药耐药基因(mdr1)和DNA拓扑异构酶Ⅱ(TopoⅡ)的表达及其临床意义。方法:采用反转录—聚合酶链反应(RT-PCR)技术检测了52例急性白血病患者mdr1基因和DNA拓扑异构酶Ⅱ的表达。结果:复发难治组白血病患者mdr1阳性率83.3 %,明显高于初治组36.7 %和完全缓解组10.0 %。复发难治组TopoⅡ表达阳性率25.0 %,低于初治组43.3 %和完全缓解组70.0 %。mdr1和TopoⅡ二者表达之间无相关性(P>0.05)。mdr1(+)/TopoⅡ(-)者预后最差。结论: mdr1阳性和TopoⅡ的表达降低均是判断疗效和预后的重要指标。mdr1和TopoⅡ之间无相关性。更多还原

【Abstract】 Objective:Toinvestigatetheexpressionofmultidrugresistance(mdr1)geneandTopoⅡinacuteleukemiaanditsclinicalsignificance.Methods:Theexpressionofmdr1geneandTopoⅡweremea-suredin52patientswithacuteleukemiabyRT-PCRtechinique.Results:Thepositiverateofmdr1geneinrefractory/relapsedgroup(83.3%)wassignificantlyhigherthanthatinuntreatedgroup(36.7%)andcom-pleteremissiongroup(10%).TheexpressionofTopoⅡinrefractory/relapsedgroup(25.0%)waslowerthanthatinuntreatedgroup(43.3%)andincompleteremissiongroup(70.0%).Nosignificantcorrelationwasfoundbetweentheexpressionofmdr1andTopoⅡ(P >0.05).Themdr1positive/TopoⅡnegativepatientsmightresultintheworstprognosis.Conclusion:Theoverexpressionofmdr1geneandthelowerexpressionofTopoⅡaretheunfavorableprognosticfactorsinacuteleukemiapatients.Thereisnocorrelationbetweenmdr1andTopoⅡexpressions.更多还原